TNF and rheumatoid arthritis: Although millions of patients with underlining conditions, including RA and CD, are treated primarily with anti-TNF-α agents, little is known about the safety of this standard therapy and susceptibility to SARS-CoV-2 infection during COVID-19 pandemic.